NCT05922995View on ClinicalTrials.gov

The Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD)

EARLY_PHASE1TerminatedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

September 30, 2023

Primary Completion Date

December 1, 2023

Study Completion Date

December 1, 2023

Conditions

REM Behavior Disorder

Interventions

DRUG

Tasimelteon

20 mg capsules taken on a nightly basis

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

Vanda Pharmaceuticals

All Listed Sponsors

collaborator

Vanda Pharmaceuticals

INDUSTRY

lead

Brigham and Women's Hospital

OTHER